Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder (BOREAL)

Trial Profile

Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder (BOREAL)

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2016

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Urinary incontinence
  • Focus Therapeutic Use
  • Acronyms BOREAL
  • Sponsors Allergan
  • Most Recent Events

    • 21 Oct 2016 Status changed from recruiting to completed.
    • 10 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2016.
    • 10 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top